Shanghai 's Visen Pharma closed a $150 million Series B financing to develop novel endocrine drugs in a round led by Sequoia China . In 2018, Visen was formed by Ascendis Pharma A/S of Denmark and an investor syndicate led by Vivo Capital and Sofinnova that contributed $40 million in capital for a 50% stake. The company's pipeline consists of three clinical-stage Ascendis-developed rare disease therapies for endocrinology indications including growth hormone deficiency. More details.... Stock Symbol: (NSDQ: ASND) Share this with colleagues: // //